Spojené štáty - angličtina - NLM (National Library of Medicine)

state of florida doh central pharmacy - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide xl is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide is contraindicated in patients with: - known hypersensitivity to glipizide or any excipients in the gits tablets. - type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

Spojené štáty - angličtina - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc) - glyburide 1.25 mg - glyburide tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide tablets are contraindicated in patients with: - known hypersensitivity or allergy to the drug. - diabetic ketoacidosis, with or without coma. this condition should be treated with insulin. - type i diabetes mellitus. - concomitant administration of bosentan.

Spojené štáty - angličtina - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 1.25 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73m2) (see warnings and precautions). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan.

Spojené štáty - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with:

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 2.5 mg - glipizide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hydrochloride tablets are contraindicated in patients with:

Spojené štáty - angličtina - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 2.5 mg - glipizide and metformin hydrochloride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ). - known hypersensitivity to glipizide or metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Spojené štáty - angličtina - NLM (National Library of Medicine)

medsource pharmaceuticals - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 5 mg - glyburide and metformin hydrochloride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. glyburide and metformin should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such prod

Spojené štáty - angličtina - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - pioglitazone hydrochloride (unii: jqt35npk6c) (pioglitazone - unii:x4ov71u42s), glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - pioglitazone 30 mg - duetact is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see clinical studies (14)] . important limitations of use pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. duetact should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. use caution in patients with liver disease [see warnings and precautions (5.5)] . reported hypersensitivity reactions with glimepiride include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions ( 5.3) and adverse reactions (6.2)] risk summary limited data with duetact or pioglitazone in pregnant women are not sufficient to determine a d

Spojené štáty - angličtina - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 2.5 mg - glipizide and metformin hcl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hcl tablets are contraindicated in patients with: 1. severe renal impairment (egfr below 30 ml/min/1.73 m2 ) (see warnings and precautions ). 2. known hypersensitivity to glipizide or metformin hydrochloride. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

Spojené štáty - angličtina - NLM (National Library of Medicine)

mutual pharmaceutical company, inc - tolazamide (unii: 9lt1bro48q) (tolazamide - unii:9lt1bro48q) - tablet - 100 mg - tolazamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin-dependent diabetes mellitus (type ii) whose hyperglycemia cannot be satisfactorily controlled by diet alone. in initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. caloric restriction and weight loss are essential in the obese diabetic patient. proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. the importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. if this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. use of tolazamide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary re